Research Results
Personalized Treatment of Depression
Neuroimaging and Treatment of Depression
Psychiatry, Psychedelics, and Spirituality
Depression, Anxiety, Metabolomics, and the Gut Microbiome
Diet and Depression
Bipolar Disorder
Post-traumatic Stress Disorder
ADHD
Pharmacogenomics
Pharmacotherapy
Clinical Trial Design
Psychiatric Education
- Balancing the beautiful and the good in pursuit of biomarkers for depression
- The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder
- Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis
- Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
- The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis
- Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression
- Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder
- Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence
- Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
- Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
- Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression
- Recovery and subsequent recurrence in patients with recurrent major depressive disorder
- Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder
- Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
- How Shall I Diagnose Thee? Let Me Count the Ways
- Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
- Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression
- Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis
- Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse
- The role of dopamine in the pathophysiology of depression
- Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence
- Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy
- Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
- Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges
- Neuroimaging Advances for Depression
- Toward a neuroimaging treatment selection biomarker for major depressive disorder
- AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale
- Neuroimaging-based biomarkers for treatment selection in major depressive disorder
- Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression
- Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
- Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
- Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
- Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
- Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids
- Metabolomic and inflammatory signatures of symptom dimensions in major depression.
- Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
- Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
- Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
- Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
- Review of nutritional supplements for the treatment of bipolar depression
- All studies are not created equal: A systematic narrative review of bipolar depression clinical trial inclusion/exclusion rules and baseline severity scores
- Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis
- Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
- Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment
- Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder
- Do alcohol use disorders destabilize the course of bipolar disorder?
- Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review
- Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder
- Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial
- An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change
- Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients
- A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans
- The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members
- When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates
- DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder
- The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions
- Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports
- Posttraumatic stress disorder increases sensitivity to long term losses among patients with major depressive disorder
- Pharmacological innovations for posttraumatic stress disorder and medication- enhanced psychotherapy
- Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
- Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial
- Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
- Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder
- Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
- The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression
- Moving on With Monoamine Oxidase Inhibitors
- Dry Those Crying Eyes: The Role of Depression and Antidepressants in Dry Eye Disease
- Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis
- Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
- Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios
- D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data
- Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
- The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder
- The effects of sertraline on psychopathic traits
- Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo
- Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population
- Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review
- Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study
- Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics
- Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population
- The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
- Tiagabine for social anxiety disorder
- Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings
- When Should a Patient Be Declared Recovered From a Major Depressive Episode?
- Antidepressant signal detection in the clinical trials vortex
- How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine
- Recall accuracy for the symptoms of a major depressive episode among clinical trial participants
- Should sensitive information from clinical trials be included in electronic medical records?
- Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials
- Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results
- A Chart-Stimulated Recall Activity to Assess Psychiatry Residents' Treatment-Based, Clinical Reasoning Skills
- A Virtual Standardized Patient-Based Assessment Tool to Evaluate Psychiatric Residents' Psychopharmacology Proficiency
- Assessing Residents' Confidence in the Context of Pharmacotherapy Competence
- Ten ways to improve the treatment of depression and anxiety in adults
- US psychiatric residents' treatment of patients with bipolar disorder
- Counseling via analogy: improving patient adherence in major depressive disorder
Personalized Treatment of Depression
- Balancing the beautiful and the good in pursuit of biomarkers for depression
- The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder
- Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis
- Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
- The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis
- Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression
- Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder
- Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence
- Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
- Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
- Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression
- Recovery and subsequent recurrence in patients with recurrent major depressive disorder
- Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder
- Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
- How Shall I Diagnose Thee? Let Me Count the Ways
- Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
- Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression
- Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis
- Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse
- The role of dopamine in the pathophysiology of depression
Neuroimaging and Treatment of Depression
- Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence
- Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy
- Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
- Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges
- Neuroimaging Advances for Depression
- Toward a neuroimaging treatment selection biomarker for major depressive disorder
- AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale
- Neuroimaging-based biomarkers for treatment selection in major depressive disorder
- Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression
Psychiatry, Psychedelics, and Spirituality
- Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
- Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
- Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
Depression, Anxiety, Metabolomics, and the Gut Microbiome
- Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
- Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids
- Metabolomic and inflammatory signatures of symptom dimensions in major depression.
- Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
- Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Diet and Depression
- Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
- Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
- Review of nutritional supplements for the treatment of bipolar depression
Bipolar Disorder
- All studies are not created equal: A systematic narrative review of bipolar depression clinical trial inclusion/exclusion rules and baseline severity scores
- Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis
- Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
- Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment
- Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder
- Do alcohol use disorders destabilize the course of bipolar disorder?
- Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review
Post-traumatic Stress Disorder
- Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder
- Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial
- An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change
- Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients
- A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans
- The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members
- When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates
- DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder
- The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions
- Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports
- Posttraumatic stress disorder increases sensitivity to long term losses among patients with major depressive disorder
- Pharmacological innovations for posttraumatic stress disorder and medication- enhanced psychotherapy
ADHD
Pharmacogenomics
- Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
- Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial
- Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
- Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder
- Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Pharmacotherapy
- The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression
- Moving on With Monoamine Oxidase Inhibitors
- Dry Those Crying Eyes: The Role of Depression and Antidepressants in Dry Eye Disease
- Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis
- Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
- Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios
- D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data
- Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
- The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder
- The effects of sertraline on psychopathic traits
- Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo
- Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population
- Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review
- Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study
- Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics
- Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population
- The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
- Tiagabine for social anxiety disorder
Clinical Trial Design
- Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings
- When Should a Patient Be Declared Recovered From a Major Depressive Episode?
- Antidepressant signal detection in the clinical trials vortex
- How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine
- Recall accuracy for the symptoms of a major depressive episode among clinical trial participants
- Should sensitive information from clinical trials be included in electronic medical records?
- Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials
- Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results
Psychiatric Education
- A Chart-Stimulated Recall Activity to Assess Psychiatry Residents' Treatment-Based, Clinical Reasoning Skills
- A Virtual Standardized Patient-Based Assessment Tool to Evaluate Psychiatric Residents' Psychopharmacology Proficiency
- Assessing Residents' Confidence in the Context of Pharmacotherapy Competence
- Ten ways to improve the treatment of depression and anxiety in adults
- US psychiatric residents' treatment of patients with bipolar disorder
- Counseling via analogy: improving patient adherence in major depressive disorder
"Precision Medicine" is the identification of biological and clinical characteristics of a patient that indicate which specific treatment is most likely to benefit that particular person.
To find out about actively recruiting studies and how you can participate in them